Slovenia Is Our Commitment; Evotec Is A Gamechanger: Sandoz’s Stenico
First Part Of Exclusive Interview With Sandoz’s Global Head For Biosimilars
Executive Summary
On the sidelines of Medicines for Europe’s 19th biosimilar conference in Amsterdam, Sandoz global biosimilars chief Peter Stenico spoke to Generics Bulletin about the firm’s preparations and strategy ahead of its proposed spinoff from Novartis later this year.
You may also be interested in...
Evotec Says Sandoz Deal Is ‘Validation’ Of Biologics Ambitions
In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
Evotec Says Sandoz Deal Is ‘Validation’ Of Biologics Ambitions
In the aftermath of announcing a major collaboration with Sandoz on biosimilars, Evotec’s chief business officer Matthias Evers speaks to Generics Bulletin about how the deal provides “validation” of Just-Evotec’s technology platform, while also outlining the firm’s wider ambitions to enable more efficient development of and broader access to biologics.
Biosimilars Loom Large As Sandoz Sets Stage For Spinoff
At a pair of capital markets days in New York and London, Sandoz has set out expectations for its post-spinoff future – with biosimilars featuring heavily in the company’s growth plans.